Wegener's granulomatosis (WG), the most common of the pulmonary granulomatous vasculitides, typically involves the upper respiratory tract, lower respiratory tract (bronchi and lung), and kidney, with varying degrees of disseminated vasculitis. Major histological features include a necrotizing vasculitis involving small vessels, extensive ''geographic'' necrosis, and granulomatous inflammation. Clinical manifestations of WG are protean; virtually any organ can be involved. Further, the spectrum and severity of the disease is heterogeneous, ranging from indolent disease involving only one site to fulminant, multiorgan vasculitis leading to death. The pathogenesis of WG has not been elucidated, but both cellular and humoral components are involved. Circulating antineutrophil cytoplasmic antibodies (cANCA) likely play a role in the pathogenesis and often correlate with activity of the disease. Treatment strategies are evolving. Cyclophosphamide (CYC) plus corticosteroids (CS) is the mainstay of therapy for generalized, multisystemic WG. Historically, the combination of CYC plus CS was used for a minimum of 12 months, but concern about late toxicities associated with CYC has led to novel treatment approaches. Currently, short-course (3-6 months) induction treatment with CYC plus CS, followed by maintenance therapy with less toxic agents (e.g., methotrexate, azathioprine) is recommended. Further, recent studies suggest that methotrexate combined with CS may be adequate for limited, non-life threatening WG. The role of other immunomodulatory agents (including trimethoprim-sulfamethoxazole) is also explored.
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WEGENER'S GRANULOMATOSIS
Wegener's granulomatosis (WG), the most common of the pulmonary granulomatous vasculitides, typically involves the upper respiratory tract (e.g., sinuses, ears, nasopharynx, oropharynx, trachea), lower respiratory tract (bronchi and lung), and kidney, with varying degrees of disseminated vasculitis. [1] [2] [3] [4] [5] [6] [7] [8] Major histological features include a necrotizing vasculitis involving small vessels (i.e., arterioles, venules, and capillaries), extensive ''geographic'' necrosis, and granulomatous inflammation. [1] [2] [3] [9] [10] [11] Clinical manifestations of WG are protean; virtually any organ can be involved. Further, the spectrum and severity of the disease are heterogeneous, ranging from indolent disease involving only one site to fulminant, multiorgan vasculitis leading to death. Many of the ''classical'' features of the disease may be lacking early in the course, but may evolve months or even years after initial presentation. [2] [3] [4] 6 Given the rarity of WG, and nonspecificity of symptoms, the diagnosis is often missed for several months after the initial symptom(s). 7 
Epidemiology
The estimated prevalence of WG in the United States is between 13 and 30 cases per million persons per 5-year period. 2, 12 In a national survey in the United States from 1979 through 1988, WG was listed as the cause of death in 1784 death certificates. 12 WG may be more common in northern Europe. Annual incidence rates of WG (per million) were 10.3 in England and 4.1 in Spain. 13 A study from Norway cited annual incidence rates as high as 12 per million (prevalence $ 95 per million). 14 The peak incidence is in the fourth through sixth decades of life 2, 4, 7, 12 ; children or adolescents are rarely affected. [15] [16] [17] [18] [19] There is no gender predominance. 6 Pediatric Age Group Few publications have focused on WG in children. 15, 16, 19, 20 Two series comprising 23 15 and 17 19 children with WG cited subglottic stenosis in 48% and 41% of cases, respectively, which is higher than the incidence in adults. In contrast, kidney involvement was observed less frequently in childhood cases (53-79%) 15, 16, 19, 20 compared with adults (> 80%).
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Historical Aspects WG was first described in 1931 by Klinger, who reported a patient with severe destructive sinusitis and uremia who had glomerulonephritis and disseminated vasculitis at necropsy. 21 In 1936, Wegener incorporated both clinical and histological criteria to describe what he believed represented a unique and distinctive syndrome. 22 In 1954, Goldman and Churg described seven new cases, reviewed 22 previously reported cases, and established pathological and clinical criteria for the diagnosis. 23 The classic histopathologic criteria included three major features: necrotizing granulomatous lesions in the upper or lower respiratory tract, generalized necrotizing vasculitis involving both arteries and veins, and glomerulitis. 23 In 1966, Carrington and Liebow described 16 patients with classic histological features of WG but sparing the kidneys (i.e., ''limited WG''). 24 Subsequent studies affirmed that this subset of patients had a more favorable prognosis compared with those with generalized WG. 4, [25] [26] [27] [28] [29] Recognizing the differing prognoses among subsets of patients with WG, DeRemee and colleagues proposed a staging classification based on the presence or absence of three specific anatomic sites [i.e., ears, nose, throat (E); lung (L), and/or kidney (K)] to stratify patients with singleor multiorgan involvement. 27 Treatment strategies (discussed in detail later) developed in the 1970s and 1980s dramatically improved the prognosis of what previously had been a fatal disease. 1, 2, 30 In 1990, the American College of Rheumatology proposed clinical criteria (in addition to the presence of small vessel vasculitis) to establish the diagnosis of WG. 5 Major diagnostic criteria included: nasal or oral inflammation; abnormalities on chest radiographs; abnormal urine sediment; and granulomatous inflammation on biopsy. In 1994, histological criteria to define different types of vasculitis were published from a panel of experts convened at the Chapel Hill Consensus Conference. 31 A requisite feature for the diagnosis of WG was the presence of granulomatous inflammation. By contrast, granulomata were absent in microscopic polyangiitis (MPA) or classical polyarteritis nodosa (PAN). 31 Another key development in the diagnosis of WG was the recognition that circulating antineutrophil cytoplasmic antibodies (cANCA) were present in a majority of patients with WG and often correlated with active disease. 6, 7, [32] [33] [34] [35] [36] By the late 1990s, an increasing number of cases of WG were diagnosed by clinical criteria and high titers of cANCA. 7 However, the specificity of cANCA has been challenged, [36] [37] [38] [39] and caution should be observed in overreliance on cANCA to diagnose WG in the absence of histological confirmation.
of patients with WG and are often the presenting features. [1] [2] [3] [4] 6, [40] [41] [42] The upper respiratory tract is the predominant or only site of involvement in some patients. 29, 43 Chronic persistent sinusitis, epistaxis, or otitis media are often the presenting and dominant clinical features of WG but are often mistaken for allergic or infectious etiologies. 2, 6 Sinus x-rays or thin section computed tomographic (CT) scans are abnormal in over 85% of patients with WG.
1,2,41 Characteristic features include thickening or clouding of the sinuses (75%) and erosion or destruction of sinus bones (25-50%). 2, 41, 44 Magnetic resonance imaging (MRI) scans of the sinuses and orbits most often reveal high-intensity lesions on T2-weighted images, consistent with mucosal thickening. 45 Granulomas are depicted as low-signalintensity lesions on T1-and T2-weighted images. Lesions typically enhance following gadolinium. 45 MRI scans are less sensitive than CT in detecting bony destruction. 45 The combination of sinus bone destruction with new bone formation on CT is nearly diagnostic of WG, especially when accompanied by an MRI scan showing a fat signal from the sclerotic sinus wall. 46 Air-fluid levels suggest secondary pyogenic infections, which are difficult to distinguish from exacerbations of WG. 2, 6, 42 Orbital involvement (often with proptosis) occurs in up to one third of patients with severe sinus WG. 18, [45] [46] [47] [48] [49] Clinical features of orbital involvement are discussed later in the ocular section.
Otologic involvement occurs in 30 to 50% of patients with WG. 2, 6, 41, 50, 51 Otalgia and refractory otitis media are common early symptoms of WG. 2 Chronic otitis media, chronic mastoiditis, or hearing loss occurs in 15 to 25% of patients. 2, 4, 50 Hearing loss may reflect vasculitis of the cochlear artery, chronic otitis media, perforation of the tympanic membrane, or chronic mastoiditis with granulation tissue or destruction of the middle ear. 2, 50, 51 Consultation with an otolaryngologist is critical because adjunctive surgical procedures (e.g., myringotomy tubes) may be helpful in patients with chronic mastoiditis and otitis media. 42 Facial nerve paralysis may reflect either or both granulomatous involvement of the middle ear and involvement of the seventh cranial nerve at the preauricular site. [52] [53] [54] [55] [56] Involvement of salivary [57] [58] [59] and parotid 54, 60, 61 glands, associated with otological or nasopharyngeal involvement, is rare. One recent review cited only 18 published cases of major salivary gland involvement in WG. 61 The nasopharynx is involved in 60 to 80% of patients with WG. 2, 4, 41, 46, 50, 62 Clinical manifestations include epistaxis, nasal septal perforation, persistent nasal congestion or pain, nasal crusting, and mucosal ulcers. 2, 6, 42 Saddle nose deformity, due to destruction of the nasal cartilage, occurs in 10 to 25% of patients with WG. 2, 4, 41, 50 Reconstruction of external nasal deformities (e.g., saddle nose) can be successfully accomplished, for either cosmetic reasons or to improve airway patency. 62 In one study, favorable outcomes were achieved with surgical reconstruction in 12 of 13 (92%) patients. 62 Surgery was performed when WG was quiescent; no flare or acceleration of the course was noted. 62 Sore throat or hoarseness may reflect ulcerations or granulomatous involvement of the pharynx or vocal cords. 2, 41, 50 Oropharyngeal ulcers involving the throat or larynx may give rise to pain, crusting, bleeding, or hoarseness. 42 ''Strawberry gingival hyperplasia'' is a rare, but nearly pathognomonic, oral lesion of WG. 42, 63 In any patient with suspected WG, a careful earsnose-throat (ENT) exam by an experienced otolaryngologist is warranted to look for mucosal ulcerations or evidence for granulomatous inflammation; any suspicious lesions should be biopsied. 42, 64 Despite the propensity for WG to affect the upper respiratory tract, histological confirmation may be difficult. Biopsies of upper airway lesions often demonstrate nonspecific findings of necrosis and chronic inflammation. 11, [65] [66] [67] [68] [69] The cardinal histological features of vasculitis or granulomatous inflammation may be lacking. A review of 126 biopsies from upper airway or nasopharyngeal lesions in patients with WG seen at the National Institutes of Health (NIH) revealed the triad of granulomas, vasculitis, and necrosis in only 16% of specimans. 11 Dual features of vasculitis plus granulomas were noted in 21% of biopsy specimens; vasculitis plus necrosis in 23%. 11 Biopsies of nasal septal perforations are rarely diagnostic. 67 In one study, 43 biopsies from clinically appearing benign nasal septal perforations demonstrated only nonspecific inflammatory changes; vasculitis was never documented, even among 12 patients with suspected WG. 67 Generous biopsies of involved sites are critical to substantiate the diagnosis. In one study of 11 WG patients with nasal involvement, the most common histological features included palisading granulomas, microabscesses, granulomatous inflammation, leukocytoclastic vasculitis (LCV) or capillaritis, and fibrinoid necrosis. 69 Histological features may have prognostic value. 69 The presence of LCV on nasal biopsy heralds disseminated disease and a poor prognosis. 69 If upper respiratory tract biopsies are nondiagnostic, biopsies of other sites may be required.
Treatment of WG involving the upper respiratory tract warrants the use of CS and cytotoxic agents (discussed in detail later). However, adjunctive therapy may be necessary. Recurrent sinus infections may require repeated courses of antibiotics for control. Patients with persistent sinus disease refractory to medical therapy may require percutaneous drainage or more definitive surgical drainage procedures. 2, 41, 50 
OCULAR INVOLVEMENT
Ocular involvement occurs in 20 to 50% of patients with WG. [1] [2] [3] [4] 47, 48, [70] [71] [72] Up to 30% of patients with ocular WG have no evidence for systemic involvement. 48, 70, 72 TREATMENT OF WG/LYNCH ET AL Clinical symptoms may result from primary vasculitis of the retinal vessels or from extension of the granulomatous process from the soft tissues or sinuses into the orbit. 49, 73, 74 Conjunctivitis, episcleritis, and scleritis occur in 15 to 20% of patients with WG. 1, 3, 47, 71 Recurrent flares of conjunctivitis and episcleritis may parallel flares of systemic disease. 1, 47 More serious complications, although rare, include necrotizing keratitis, corneoscleral perforation, posterior uveitis, or optic neuritis. 47, 75, 76 Retinal hemorrhages and exudates or papilledema on ophthalmological examination suggest retinal vaculitis. 47 The superficial ocular complications (e.g., conjunctivitis, episcleritis) often respond to topical corticosteroids; involvement of the deeper ocular structures warrants both systemic CS and cytotoxic therapy. 1, 47, 77 Proptosis from a retroorbital granulomatous inflammatory process develops in 10 to 22% of patients during the course of the disease and may result in permanent sequelae. 1, 2, 18, 47, 48 Compression or primary involvement of the optic nerve may lead to blindness in 2 to 9% of patients. [1] [2] [3] 47, 48, 70, 71 Granulomatous involvement of the orbit may cause anterior displacement of the eye, pain, swelling, proptosis, oculomotor palsies, blurred vision, diplopia, and reduction of eye motility. 1, 18, 47, 70, 71 In some cases, impingement on the blood supply to the optic nerve by large mass lesions warrants surgical decompression. 47 Primary vasculitis of the posterior ciliary arteries supplying the optic nerves may also lead to visual loss.
1,2,47 CT or MRI scans are important to distinquish these entities. 45, 48 Nasolacrimal duct obstruction occurs in 25 to 52% of patients with orbital WG. 48, 71, 78 Disease localized to the orbit may be difficult to diagnose because serum cANCA are often negative. 70 In a series of 29 patients with orbital WG, circulating cANCA were detected in nine of 10 with generalized disease but in only six of 19 (32%) with limited WG. 48 Orbital biopsies in WG demonstrate the cardinal features of necrosis, granulomatous inflammation, and vasculitis in fewer than 50% of patients. 48, 79, 80 Frequently, orbital biopsies reveal nonspecific findings of mixed inflammatory cells, areas of necrosis, and microabscesses. 48, 79 However, sinusitis is present in > 85% of patients with proptosis due to WG. 48 In such cases, biopsies of sinuses may substantiate the diagnosis. 48 Early consultation with an opthalmologist is essential in any patient with suspected WG to assure prompt diagnosis of any ocular abnormalities and provide long-term follow-up.
INVOLVEMENT OF TRACHEA AND BRONCHI
Granulomatous involvement of the trachea or major bronchi leads to stenosis in 10 to 30% of patients with WG. 2, 6, 41, [81] [82] [83] [84] Symptoms are nonspecific and include dyspnea, wheezing, stridor, and change in voice. 82, 83, 85 Stenosis of large airways may develop years after the initial diagnosis of WG and may develop in the absence of manifestations of WG at other sites. 83, 85 However, concomitant involvement of the nasopharynx or sinuses is nearly invariably present. 41, 82 Among 43 patients with subglottic stenosis (SGS) seen at the NIH, 42 (98%) had sinus involvement; saddle nose deformity was present in 47%. 82 The site of tracheal stenosis is usually circumferential and localized, extending 3 to 5 cm below the glottis. 41, 82, 83, 86 However, more extensive involvement of the distal trachea or mainstem bronchi may occur. 83, 84 A study from the Mayo Clinic cited endobronchial abnormalities in 30 of 51 patients (59%) with WG undergoing bronchoscopy. 83 Four (13%) had tracheal or bronchostenosis. Importantly, extensive endobronchial abnormalities were noted in 11 patients with normal chest radiographs. Ulcerating tracheobronchitis was the most common lesion and eventuated in progressive stenosis in seven patients. Persistent dyspnea or wheezing may reflect cicatricial scarring at the site of previous endobronchial inflammation. Stridor or wheezing suggests stenosis of large airways (trachea or mainstem bronchi). 85 Flow-volume loops may detect physiologically significant upper airway obstruction, but are insensitive. With tracheal (subglottic) stenosis, both inspiratory and expiratory limbs of the flow-volume loop are truncated (flow rate limitation) 82 ( Fig. 1   86a ). When stenosis is suspected, flexible fiberoptic bronchoscopy (FFB) should be performed. Among 27 WG patients with SGS who had FFB, circumferential narrowing of the trachea due to a mature scar was observed in 20 (74%) cases; friability or acute inflammation was noted in only seven patients (26%). 85 Histological confirmation of tracheal or endobronchial WG is difficult; biopsies usually demonstrate nonspecific changes (e.g., necrosis or inflammation). In one study of 26 WG patients with SGS, dual features of vasculitis and granulomatous inflammation were present in only seven of 140 (5%) subglottic biopsies. 82 In a series from the Mayo Clinic, 26 subglottic biopsies were performed in 16 patients with WG and SGS; granulomatous inflammatory changes were observed in only four biopsies (15%). 85 In another study from the Mayo Clinic, endobronchial biopsies fulfilled specific histological criteria for WG in only three of 17 patients (18%). 83 Serum titers of cANCA did not correlate with endobronchial inflammation. 83 Thus the diagnosis of tracheal or endobronchial involvement in patients with known WG in some cases must be presumed in the appropriate clinical context, even when histology is less than definitive. Importantly, progressive subglottic or bronchial stenosis can develop even when the disease is quiescent at other sites. 82, 83, 85 The severity and extent of airway narrowing are best evaluated using multiplanar and three-dimensional reconstructions of spiral CT scans using thin sections [86] [87] [88] [89] [90] (Figs. 2A,B) . Serial CT scans may be useful to follow patients longitudinally. 88 A new threedimensional image reconstruction and display technique called virtual bronchoscopy produced from high-resolution CT is a noninvasive means to assess presence and extent of airway stenoses with sensitivity at least to segmental bronchi. 89 Severe stenosis of large airways requires urgent and aggressive intervention. 85 Life-threatening upper airway obstruction can develop, not only from the subglottic lesion but also from crusted, thickened secretions from mucosal inflammation in the upper or lower respiratory tract. 82, 83 The impact of medical therapy in altering the course of endobronchial or endotracheal WG is not clear. Aggressive immunosuppressive therapy is warranted when an active inflammatory component is demonstrable or when disease is present at other sites. However, disease localized to the airways may not respond to medical treatment. In this circumstance, alternative treatment modalities include carbon dioxide (CO 2 ) or neodymium:yttrium-aluminum-garnet (Nd:YAG) laser, dilatation, intratracheal CS injections, placement of Silastic airway stents, tracheostomy, laryngeal-tracheal reconstruction, and partial tracheal resection. 2, 41, [81] [82] [83] 85, 91, 92 When possible, surgical intervention or manipulation of the airways should be minimized during flares of systemic disease activity. 85 Silastic stents may provide sustained relief of symptoms in some patients but are associated with numerous complications (e.g., migration of the stent, granuloma formation, mucus hypersecretion, fungal colonization, bronchomalacia in the area of the stent). 83 Tracheal reconstruction has been successfully performed in patients with severe tracheal stenosis refractory to medical therapy but is a formidable undertaking. 82, 85 Intralesional injection with long-acting CS and intratracheal dilatation is efficacious in treating SGS. Utilizing this approach, two series comprising 21 82 and 20 93 patients, respectively, noted that luminal patency was maintained and no patient required tracheostomy. Long-term follow-up by an otolaryngologist is essential to monitor response to therapy and assess the need for future therapeutic interventions.
LUNG INVOLVEMENT
Pulmonary involvement is noted in 55 to 90% of patients with WG. 1, 2, 4, 6, 84 The spectrum of pulmonary manifestations is broad and includes asymptomatic nodules or infiltrates on chest radiographs or CT scans, cough, hemoptysis, dyspnea, impaired pulmonary function, endobronchial inflammation and bronchostenosis, parenchymal necrosis, and diffuse alveolar hemorrhage. 1, 2, 4, 6, 84 Pulmonary function tests may demonstrate airflow obstruction (particularly when endobronchial involvement is prominent), restriction, or mixed patterns. 84, 94 Abnormalities on chest radiographs are noted in more than 70% of patients at some point during the course of the disease. Chest CT scans are far more sensitive than chest x-rays in depicting the nature and extent of the pulmonary process. Multiple pulmonary nodules (with or without cavitation) are the most characteristic findings on CT; other features of active WG include focal infiltrates, consolidation, or ground-glass opacities (GGOs). 95, 102 In one study of pulmonary WG, 102 nodules or masses were detected on chest CT scan in 27 of 30 patients (90%); cavitation was present in one or more nodules in 13 of 27 (58%) patients. The nodules ranged from one to 32 in number (mean 8) and had a predominantly subpleural or peribronchial distribution. Thickening of bronchial walls in the segmental or subsegmental bronchi was noted in 22 patients (73%); large airways were involved in nine patients (30%). Other features included consolidation in seven (22%) and GGOs in seven (22%). With treatment, 16 of 20 (85%) of pulmonary parenchymal lesions regressed. 102 In another series of 28 patients with pulmonary WG, 95 the most most common aberrations included nodules (70%), infiltrates (25%), pleural disease (25%), and interstitial pattern (18%). Additional manifestations of WG include focal or diffuse neumonic infiltrates, large mass lesions (Figs. 10A-C 102a ), pleural effusions, stenosis of the trachea or bronchi, atelectasis, septal bands, parenchymal scarring, and irregular pleural thickening. 87, 90, 98, [102] [103] [104] With treatment, GGOs, cavitating nodules, nodules > 3 cm in diameter, or consolidation typically resolve or regress whereas linear lines or smaller nodules persist, suggesting residual fibrosis. 98, 103, 105 Positive uptake on F 18 positron emission tomography (PET) scans, mimicking malignancy, was noted in one patient with WG. 106 Surgical lung biopsy (SLB) is optimal to establish a firm diagnosis of pulmonary WG. When focal pulmonary infiltrates or nodules are present, vasculitis and necrotizing granulomas are found on SLB in more than 90% of patients. 10 Micronecrosis or microabscesses containing neutrophils and mononuclear cells appear to be early lesions, followed by accumulation of histiocytes forming so-called palisading granulomas. 9 Later findings include geographic necrosis, granulomatous infiltration, vasculitis, and varying degrees of fibrosis. 10 A review of 87 SLBs in pulmonary WG cited the following features: vascular inflammation (acute or chronic) in 94%, parenchymal necrosis (84%), scattered giant cells (79%), areas of geographic necrosis (69%), granulomatous microabscesses with giant cells (69%), neutrophilic microabscesses (65%), poorly formed granulomata (59%), capillaritis (31%), and fibrinoid necrosis (11%). 10 Bronchiolar abnormalities were more common than previously appreciated. In that study, bronchial or bronchiolar abnormalities included nonspecific chronic inflammation (64%), acute inflammation (51%), bronchiolitis obliterans (31%), and follicular bronchiolitis (28%). Confluent, sarcoidlike granulomas were rarely observed (< 5%). Additional nonspecific features that may be found in WG include cryptogenic organizing pneumonia (COP), 107, 108 eosinophilic infiltration, 108 chrondritis involving bronchial cartilage, 109 and interstitial fibrosis. 10, 110 Treatment with CS or cytotoxic agents influences the histopathological response. 110 In a study of 20 SLBs from patients with WG following treatment with CS or cyclophosphamide (CYC), inflammation or fibrosis was present in all cases, but only four (20%) had macronodular necrosis (a hallmark of WG). 110 Histological features may be muted with therapy. Palisading granulomas may convert to giant typically reveals increases in neutrophils (22-42%) and eosinophils (3-4%) 84, 113, 114 ; BAL lymphocytosis may also occur. 114 BAL fluid from patients with active pulmonary WG reveals high concentrations of cANCA, 113 immunoglobulin G (IgG), IgA, and albumin 115 ; elevated myeloperoxidase (MPO), peroxidase activity, eosinophil cationic protein (ECP), and soluble interleukin-2 receptor (sIL-2R). 114 These findings shed light on the pathogenesis of WG but are not specific. Transthoracic core needle biopsy (guided by CT or fluoroscopy) has demonstrated inflammation or vasculitis in a few cases 116 but specificity is suboptimal. With few exceptions, bronchoscopic or percutaneous needle aspiration biopsies are inadequate to substantiate the diagnosis.
ALVEOLAR HEMORRHAGE
Diffuse alveolar hemorrhage (DAH) is a rare but potentially fatal complication of WG, reflecting diffuse injury to the pulmonary microvasculature. 100, 117 In this setting, rapidly progressive glomerulonephritis is present in more than 90% of patients. 84, 99, 100 By contrast, fewer than 40% manifest upper airway symptoms. 99 Chest radiographs in DAH demonstrate bilateral alveolar infiltrates; the classic nodular or cavitary lesions of WG are lacking 99 (Figs. 11, 12 ). The role of SLB in the setting of DAH is controversial. Histopathological features of alveolar hemorrhage and inflammation and necrosis of the alveolar capillaries and walls (termed capillaritis) predominate, but these are nonspecific 100 ( Fig. 13 ). Interestingly, in most cases of WG that manifest as DAH, granulomatous vasculitis or extensive parenchymal necrosis are absent. 100 For severe DAH, we believe the risk of SLB outweighs the benefit. A presumptive diagnosis of DAH can often be made on the basis of clinical and radiographic features, circulating cANCA, and bronchoscopy with BAL. Large numbers of hemosiderin-laden macrophages, bloody or serosanguinous BAL fluid, and absence of infectious etiologies support the diagnosis of DAH (Figs. 14A,B) . Biopsy of extrapulmonary sites of involvement may also help substantiate the diagnosis. Percutaneous renal biopsy is warranted if the urinary sediment demonstrates microscopic hematuria, or renal insufficiency is present. Rapidly progressive glomerulonephritis (GN), with negative immunofluorescent stains (i.e., pauci-immune) is characteristic of WG in the context of DAH. 99, [118] [119] [120] DAH is a medical emergency requiring aggressive therapy with intravenous ''pulse'' methylprednisolone (1 g daily for 3 days), 99, 120 while pursuing a diagnostic workup and awaiting the results of biopsies and ancillary laboratory results. Conventional therapy with oral CYC and a tapering regimen of CS 1 is appropriate once the diagnosis of WG has been confirmed.
RENAL INVOLVEMENT
Glomerulonephritis (pauci-immune) occurs in 70 to 85% of patients at some point in the course of the disease, but only 11 to 17% of patients exhibit severe Figure 11 Posteroanterior chest radiograph from a 70-year-old woman demonstrates extensive airspace consolidation, particularly involving the right lung. Sinus and lung biopsies demonstrated areas of necrosis and granulomatous vasculitis. Although she initially improved with medical therapy, she died 6 weeks later of opportunistic infection. Figure 12 Posteroanterior chest radiograph from a 64-year-old woman with rapidly progressive glomerulonephritis and hemoptysis demonstrates focal airspace consolidation in the left midlung field, with excavation, and alveolar infiltrate in the right lung. Renal function improved dramatically with cyclophosphamide and corticosteroid therapy. Unfortunately, bacteremia due to Pseudomonas aeruginosa developed 2 weeks after initiation of therapy, and she died of sepsis. renal insufficiency at presentation. [1] [2] [3] [4] 6, 118, 119, 121 Extrarenal manifestations usually precede the renal manifestations, often by several months. In contrast to Churg-Strauss syndrome (CSS) or PAN, hypertension is uncommon in WG, cited in fewer than 10% of patients at presentation. 1, 2 The characteristic renal lesion of WG is a segmental focal GN. 2, 122 Microscopic hematuria, proteinuria, or red cell casts precede detectable elevations in serum creatinine.
1,2,118,119 Athough abnormalities in renal function often parallel the severity of lesions on renal biopsy, abnormalities on renal biopsies may be observed even in patients with normal urinary sediment and renal function. 1, 123 With more fulminant forms, a necrotizing, crescentic GN is observed 118, 119, 122 (Fig. 15) . Immune complexes are absent or infrequent, consistent with ''pauci-immune GN. '' 124 These histological findings are nonspecific and can be found in diverse immune-mediated or infectious disorders. Granulomatous vasculitis is observed in only 6 to 15% of renal biopsies from patients with WG. 1, 2, 121, 122 In a retrospective review of 94 renal biopsies from patients with WG and renal involvement, most common features included segmental necrotizing GN and extracapillary proliferation, present in 85% and 92% of biopsies, respectively. 122 Serum creatinine at biopsy correlated with the percent of glomeruli with crescents or with necrosis. 122 The onset and course of renal involvement are variable. In some patients, the course is indolent (progressing over months to years) 2, 122, 125 whereas others manifest rapidly progressive GN, progressing to end-stage renal failure (ESRF) within days to weeks. 118, 119 Aggressive and prompt institution of therapy with CS and cytotoxic agents is mandatory to avert irreversible renal damage. Even in oliguric renal failure, substantial recovery of renal function can be achieved in many patients. 122 The initial serum creatinine does not predict long-term outcome (i.e., loss or restoration of renal function). 126 Unfortunately, 11 to 32% of patients with WG develop ESRF requiring chronic dialysis. 2, 119, 122, 125, 127, 128 Chronic dialysis-dependent renal failure is more common in patients with severe loss of glomeruli on initial renal biopsy. 122, 129 Prognosis with dialysis-dependent renal failure is poor. 126 One retrospective study followed 23 patients with WG requiring dialysis. 126 At long-term follow-up, 11 (48%) had died; seven (30%) remained dialysis-dependent; only five (22%) had substantially improved renal function. 126 Chronic renal failure months or years after the initial injury may reflect nephrosclerosis from the original renal injury rather than recurrent WG. 1, 125 Renal transplantation may be considered for patients with ESRF and no evidence for active WG. 125, 128 Recurrence of WG has been rare following transplantation. Other rare urological complications of WG include anecdotal reports of necrotizing vasculitis involving the ureters, 130 ureteral stenosis, 131 renal artery aneurysms with rupture, 130, 132 penile necrosis 132 or ulcers, 131 acute urinary retention, bladder pseudotumor, 131 and renal masses. 133, 134 Involvement of the prostate is rare. 2, 131, 135 One recent review identified 18 cases in the literature with histological evidence of WG in the prostate gland: 13 patients (72%) had symptomatic urinary tract obstruction, three (17%) had microscopic hematuria, and two (11%) had no urinary tract symptoms. 135 Medical therapy for WG involving the urinary tract is usually efficacious. Surgical intervention (e.g., suprapubic cystotomy; ureteral stents, transurethral prostatic resection, etc.) may be required in selected cases. 131 
CENTRAL OR PERIPHERAL NERVOUS SYSTEM INVOLVEMENT
Central or peripheral nervous system involvement occurs in fewer than than 4% of patients at initial presentation, but eventually develops in 10 to 54% . 1, 2, 84, 136, 137 In a classical review of 104 patients with WG, Drachman 138 identified three patterns of central nervous system (CNS) involvement: (1) vasculitis (28%); (2) granulomatous lesions from contiguous invasion from nasal, paranasal, or orbital disease (26%); and (3) granulomatous lesions remote from nasal granulomas (involving brain or meninges) (4%). Mononeuritis multiplex or polyneuritis account for more than 50% of neurological complications. 1, 2, 136, 137 Peripheral neuropathy (PN) usually presents early in the course of the disease and may be the presenting feature. 137 Risk factors of PN include male gender, older age, greater extent of disease, and higher titers of ANCA. 137 Cerebral or meningeal involvement occurs in 2 to 8% of patients with WG 1,2,136,139 and may be the presenting feature. 140 In a prospective study of 128 patients with WG, peripheral neuropathy was noted in 56 patients (43%); CNS involvement in nine (7%). 137 Meningeal thickening or enhancing lesions on CT are usually focal, adjacent to nasal, orbital, or sinus disease. 139, 140 Clinical manifestations include cerebral infarction or hemorrhage, cranial nerve palsies, 136 Two series comprising 324 136 and 85 patients 1 cited cranial nerve palsies in 6.5% and 9.4%, respectively. Oculomotor disturbances may be the presenting feature of WG localized to the CNS. 70 Mild (subclinical) cognitive impairment has been noted in some patients with WG; in this context, brain MRI scans reveal multiple periventricular or juxtacortical white matter lesions. 149 Involvement of the spinal cord microvasculature may give rise to myelopathy, quadriparesis, or paraparesis. 136, 139, 151 Vasculitis of the CNS is rarely confirmed histologically because of inaccessibility or risks associated with biopsies. 139, 142, 151, 152 The diagnosis is usually supported by histological confirmation at extraneural sites or by noninvasive studies [e.g., electromyogram (EMG), MRI, or CT scans of the brain or spinal cord] in patients with neurological symptoms and previous documentation of WG. 139, 150, [153] [154] [155] MRI scans reveal a wide spectrum of findings including diffuse or focal dural thickening and enhancement, discrete lesions, infarcts, nonspecific white matter areas of high signal intensity, enlarged pituitary gland with infundibular thickening, and cerebral atrophy. 139, 141, 151, 154, 156 Cerebral angiography is ill advised because the small vessels affected in WG are below the sensitivity of angiography. 140, 151 In some patients, biopsy of the sural nerve or other affected nerves may substantiate the diagnosis. 136 
SKIN INVOLVEMENT
Cutaneous lesions are present in 14 to 50% of patients during the course of the disease. 1, 2, 4, 157, 158 Manifestations are protean and include palpable purpura, subcutaneous nodules, papules, petechiae, ulcers, and nonspecific erythematous or maculopapular rashes.
2,157-160 Severe ulcerating lesions resembling pyoderma gangrenosum have been described. 52, 158, 159, 161, 162 Skin biopsies may demonstrate granulomatous vasculitis with necrosis; however, leukocytoclastic vasculitis (LCV) (a nonspecific lesion) is more common. 2, 157, 159, 160, 163 In a series of 46 patients with WG and dermatological manifestations, the most common features on skin biopsies were LCV (31%), chronic inflammation (31%), granulomatous inflammation (19%), acute inflammation without vasculitis (9%), and miscellaneous (11%). 163 Importantly, granulomatous vasculitis was never observed. 163 Another series of 35 patients with WG involving skin or mucous membranes cited the following aberrations: palpable purpura (n ¼ 26), oral ulcers (n ¼ 15), skin nodules (n ¼ 6), skin ulcers (n ¼ 5), gingival hyperplasia (n ¼ 3), and miscellaneous (n ¼ 5). 158 Subcutaneous nodules and popular lesions reflect granulomatous inflammation of the dermis. 159, 160 Petechiae and purpuric or hemorrhagic lesions indicate vasculitis with necrosis and fibrinoid change. 159, 160 Skin changes may parallel the course of the systemic disease and have prognostic significance. 2, [158] [159] [160] 163 In a cohort of 46 patients with WG and dermatological involvement, LCV correlated with a younger age at the onset of disease, active disease, more rapid progression of disease, higher frequency of articular and musculoskeletal symptoms compared with patients with no skin involvement (n ¼ 82), or granulomatous inflammation (n ¼ 19). 163 In contrast, only 64% of patients with granulomatous inflammation on skin biopsies had evidence for active systemic disease. 163 Cutaneous lesions in WG are associated with a higher incidence of articular and renal involvement compared with WG patients without cutaneous involvement. 158 
CARDIAC INVOLVEMENT
Cardiac involvement is rarely documented antemortem, but prevalence rates of 8 to 15% have been estimated. 2, 4, [164] [165] [166] [167] [168] Any portion of the heart may be involved, but coronary arteritis and pericarditis are the most common clinical features. [164] [165] [166] [167] [168] Classic ST and T wave changes may reflect pericarditis. 164, 165 Necrotizing vasculitis or granulomatous inflammation involving the myocardium or coronary arteries may give rise to conduction defects, 165, 169, 170 fatal arrhythmias, 171 or cardiomyopathies. 2, 164, 165, 172 Necrotizing vasculitis affecting cardiac valves has been described. 166, 173, 174 In one study, echocardiography detected valvular abnormalities in eight of nine patients with WG; severe aortic insufficiency requiring surgical valve replacement was documented in three patients. 166 An inflammatory mass involving aortic valve and myocardium mimicking atrial myxoma has been described. 175 
INVOLVEMENT OF LARGE VESSELS
Involvement of the aorta or large arteries is common in Kawasaki's syndrome, Behçet's syndrome, giant-cell (temporal) arteritis, and Takayasu's arteritis, 176 but is rare in WG. However, case reports of WG involving the internal carotid artery leading to stenosis, 177 abdominal aorta (with dissection), 178 or mesenteric arteries 179 have been published.
GASTROINTESTINAL INVOLVEMENT
Gastrointestinal (GI) manifestations (e.g., abdominal pain, diarrhea, hemorrhage, and perforation) were cited in 4 to 10% of patients with WG. 2, 4, [180] [181] [182] Two series cited GI involvement in four of 45 180 and four of 36 patients 181 with WG. Histological confirmation of WG involving the GI tract is rarely documented antemortem. [180] [181] [182] However, in a review of 59 necropsies in patients with WG, granulomatous or vascular lesions within the GI tract were detected in 23 (39%). 183 Rarely, GI involvement (e.g., colitis, bleeding) may be the presenting feature of WG. 182 Hepatic involvement is not a feature of WG. However, isolated case reports of patients with WG and incomplete septal cirrhosis, 184 primary biliary cirrhosis, 185 and portal inflammatory granuloma, vasculitis, and fibrosis 186 have been published. Splenic involvement is rarely diagnosed antemortem, [187] [188] [189] [190] but splenic infarcts have been documented at necropsies 191, 192 or on abdominal CT (low attenuation lesions with peripheral enhancement). 187, 193 OTHER ORGAN INVOLVEMENT Constitutional symptoms (e.g., malaise, fatigue, fever, weight loss) occur in 30 to 80% of patients with WG and may be the presenting features.
1,2 Nondeforming polyarthritis involving medium-and large-size joints occurs in two thirds of patients and parallels activity of the systemic disease.
1,2 Articular symptoms usually remit with cytotoxic or CS therapy.
HISTOPATHOLOGY
The cardinal histopathologic features of WG include a necrotizing vasculitis affecting arterioles, venules, and capillaries; granulomatous inflammation; foci of parenchymal necrosis; microabscesses; and areas of fibrosis with acute and chronic inflammation.
1,2,9,10 Irregularly shaped (geographic) necrosis surrounded by granulomatous inflammation is characteristic (Fig. 16) . Wellformed sarcoidlike granulomas are rare, but multinucleated giant cells, epithelioid cells, and collections of histiocytes impart a granulomatous character to the inflammatory process 1,2,9,10 ( Fig. 9B ). Vascular walls are infiltrated (and may be destroyed) by mononuclear cells and neutrophils, with occasional multinucleated giant cells and eosinophils (Fig. 17) . Both acute and healing phases of the vasculitic lesions may be observed in individual patients. Fibrinoid necrosis and thrombosis within vascular lumens are early findings 9 ( Fig. 18) . Later, fibrosis of vascular walls may result in stenosis or obliteration of the lumens (Fig. 19) . Elastic stains may be required to identify remnants of destroyed vascular walls. 1 A pronounced fibroblastic component, with concentric rings of collagen and connective tissue matrix, may be present. These histological features may not be found if small or nonrepresentative biopsies are obtained. Granulomas and vasculitis of small vessels may be observed with infections (particularly due to mycobacterial and fungal etiologies). 194 Thus special stains should be performed in any granulomatous or necrotic lesion to exclude infectious causes. With infectious granulomas, vasculitis is a secondary phenomenon contiguous with foci of necrosis; sarcoidlike granulomas are frequently observed. 9, 194 Laboratory Features Anemia, thrombocytosis, or leukocytosis can be identified in 30 to 40% of patients with WG.
1,2,4,6,84 Leukopenia or thrombocytopenia is rare in untreated patients, but may develop as a consequence of cytotoxic therapy.
1,2
Peripheral blood eosinophilia is not a feature of WG. Polyclonal hypergammaglobulinemia occurs in up to 50% of patients.
1,2 Serum complement levels are normal or elevated.
1,2 Renal function tests (serum creatinine, blood urea nitrogen) and urinalysis should be obtained in all patients initially. Striking increases in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are characteristic of active, generalized disease and usually correlate with disease activity. 2, 118, 195, 196 CRP concentrations change more rapidly than ESR in response to changes in disease activity. 196 However, ESR or CRP can be normal with active disease, particularly when only a single site is involved. 83 Serial determinations of the ESR or CRP are useful in monitoring the disease but are nonspecific because elevations may occur in the presence of coexisting infections. 118, 195 Autoantibodies directed against cytoplasmic components of neutrophils (cANCA) are helpful in the initial diagnosis of WG and in monitoring response to therapy. 6, 36 Increases in cANCA were noted in more than 90% of patients with active generalized WG, and in 40 to 70% of patients with active regional disease. 33, [197] [198] [199] Among WG patients with circulating ANCA, > 90% are directed against proteinase 3 (PR3); < 10% are directed against MPO or other antigenic epitopes. 36, 37, 200, 201 Changes in cANCA usually correlate with disease activity and are unaffected by intercurrent infections. 197, 198 However, cANCA titers may persist in 30 to 40% of patients even after complete clinical remissions have been achieved. 6, 197, 199, 202 Further, increases in cANCA titers do not necessarily presage relapse. 197, 199, 202, 203 Serial determinations of cANCA provide useful adjunctive information to the clinical data, but treatment decisions should not rely exclusively on cANCA titers. 6, 203, 204 
RADIONUCLIDE SCANS

Gallium
67 citrate scintigraphy may show uptake in lung or sinuses in patients with active WG, but clinical value is unproven. In one retrospective study, Ga 67 scans were examined from 40 episodes of presumed active WG in 28 patients. 205 Positive (increased uptake) Ga 67 scans were noted in eight episodes (20%). Negative predictive value was 100%, but positive predictive values for lungs or paranasal sinus involvement were 24% and 63%, respectively. 205 False-positive findings were related to bacterial or viral infections. Although a negative scan strongly supports inactive disease, Ga 67 scans are expensive, nonspecific, and logistically difficult (scanning is done 72 hours after injection). We see no role for radionuclide testing in the diagnosis or follow-up of WG.
STAGING OF ACTIVITY
The Birmingham Vasculitis Activity Score (BVAS) has been used as a disease-specific activity index for WG. 3, 206 Parameters are weighted according to minor or major componcents. A modified BVAS was shown to be a valid, disease-specific activity index for WG, with good inter-and intraobserver variability. 207 The use of objective scoring systems may be invaluable in longitudinal follow-up.
PATHOGENESIS OF WG
The cause of WG is unknown. Two key histopathologic features of granulomas and vasculitis suggest an exaggerated cellular immune or hypersensitivity response, but no identifiable antigen or pathogen has been identified. The preponderance of disease in the upper and lower respiratory tracts suggests that inhaled antigen(s) may inititate the cellular immune response. 6 T cells, monocytes, and neutrophils constitute key cellular elements in the infiltrate in WG, suggesting that both cell-mediated and neutrophil-mediated immune mechanisms are operative. Early injury is likely mediated primarily by polymorphonuclear leukocytes (PMNs) but late phases of the vasculitic process involve principally mononuclear cells (both mononuclear phagocytes and lymphocytes). The granulomatous component in WG is mediated by CD4 þ T cells that produce Th1 cytokines [e.g., interleukin-2 (IL-2), g-interferon (IFNg), but not IL-4, IL-5, or IL-10]. 208 Circulating cANCA suggests a role for PMNs and these autoantibodies in the pathogenesis and evolution of WG. 6, 209, 210 The binding of PR-3 ANCA activates PMNs and endothelial cells, eliciting cytokine release and injury. 6, 211 Increases in serum immunoglobulins, B cell activity, and cANCA suggest that humoral mechanisms are also operative. 6, 121 Immune complexes (ICs) have been identified in serum 118, 124 or skin 212 in some patients with WG but are generally absent in involved lung or renal tissue. 123 Activation of the coagulation cascade may play a role. Deposition of fibrin, platelets, and activated coagulation products may modulate glomerular injury. 118, 211 Chronic suppurative disease in the upper or lower respiratory tracts may provide an antigenic source, leading to an exaggerated immune response mediated by cANCA. Exacerbations of WG during intercurrent infections 118, 195 and the frequent relapses observed in WG patients who are chronic nasal carriers of Staphylococcus aureus 213 suggest that infections may amplify the inflammatory process, possibly by eliciting an antibody and acute phase response. 214 Abundant experimental, in vitro, and clinical data suggest that cANCA play critical roles in the development of WG and other ANCA-associated vasculitides (e.g., MPA and CSS) (discussed in depth by Dr. Jeannette in this issue). 36, 203, 204, 215, 216 PR3, one of the neutral serine proteinases in azurophilic granules of human PMNs and monocytes, is the target antigen for ANCA in WG. 36, 203, 209, 215 Circulating PR3-ANCA are present in 70 to 93% of patients with untreated WG, and titers often correlate with disease activity. [32] [33] [34] [35] [36] Conversely, antibodies directed against MPO (MPO-ANCA) are rare in WG 36 but are detected in > 50% of patients with MPA, CSS, or pauci-immune GN. [217] [218] [219] [220] [221] PR3-ANCA is infrequent (10-20%) in these disorders. 36, [217] [218] [219] [220] [221] Experimental in vitro data suggest that PR3-ANCA induces a sequence of events including recruitment and activation of PMNs and monocytes, release of oxygen (O 2 ) radicals and lysosomal enzymes, and endothelial cell (EC) injury. 209, 222 BAL demonstrates marked increases in PMNs in patients with active WG and circulating cANCA. 113 Further, plasma tumor necrosis factor-a (TNFa) is elevated in patients with active WG 223 . ''Priming'' of PMNs by cytokines such as TNFa or IL-1 is necessary for expression of PR3 or MPO on cell membranes. 209, 224, 225 PR3-ANCA stimulates production of the chemokines monocyte chemoattractant peptide-1 (MCP-1) 226 and IL-8 by monocytes. 227 ECs, mesangial cells, epithelial cells, and PMNs are capable of producing IL-8, particularly
TREATMENT OF WG/LYNCH ET AL following cytokine stimulation. 211 IL-8 plays a key role in neutrophil sequestration in the microvasculature. TNFa-primed PMNs downregulate expression of the IL-8 receptor CXCR2, reducing their ability to respond to a chemotactic gradient, 228 favoring retention of PMNs with the microvasculature. In vivo, these processes may trap PMNs within glomerular capillaries or other sites of disease. 211 Exposure of cytokine-primed PMNs and mononuclear phagocytes to ANCA IgG induces full activation with a respiratory burst, release of O 2 radicals, degranulation, and release of proinflammatory cytokines. 229, 230 After degranulation of PMNs, release of PR3 causes EC injury and tissue damage. 209, 222, 231, 232 The cytotoxic effects of PR3 on ECs are mediated by both lytic necrosis 209 and apoptosis. 233 Scavenging macrophages engulf apoptotic PMNs that express ANCA on the cell surface. 234 Phagocytosis of PR3-ANCA-opsonized PMNs by macrophages (MOs) elicits the release of TNFa and other proinflammatory mediatiors, and may prime and recruit additional PMNs 235 and augment tissue damage. 211 In addition, diverse nonimmune cells express PR3 and may contribute to the inflammatory process.
The endothelium is not an innocent bystander in the vasculitis process but plays an active role in augmenting tissue injury. 211, 236 Upregulation of adhesion molecules [e.g., intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)] contributes to the PMN-mediated cytotoxic process. 237 Endothelial cells produce platelet activating factor (PAF) and IL-8 following stimulation by proinflammatory cytokines 238 or reactive O 2 intermediates. 211 Both PAF and IL-8 mediate increased EC/PMN adhesion by triggering increasing affinity for CD11b/CD18. 211, 237 These molecules are chemotactic for PMNs, prime PMNs, and trigger PMN adhesion. In addition, cANCA-induced stimulation of IL-1b, TNFa, IFNg, and chemokines augments EC expression of the leukocyte adhesion molecules ICAM-1, VCAM-1, and Eselectin. 239, 240 Serum concentrations of ICAM-1, VCAM-1, and E-selectin are elevated in WG and correlate with disease activity. 241 Elevated levels of soluble (s) E selectin, sICAM-1, and sVCAM-1 were demonstrated in active WG and MPA compared with healthy controls. 242 Further, the levels of sE-selectin, sICAM-1, and sVCMA-1 correlated with disease activity and normalized as the disease remitted. Human ECs express PR3, and anti-PR3 antibodies activate ECs in vitro. 243, 244 Upregulation of PR3 by proinflammatory cytokines (e.g., TNFa and IL-1) induces PR3, 224 leading to tissue damage. 245 Both PR3 and elastase were detected extracellularly in renal tissue in patients with WG and MPA, 246 suggesting that these enzymes contribute to tissue injury. Strong expression of PR3 mRNA by glomerular epithelial cells in patients with WG and crescentic GN 246 suggests that non-immune cells expressing PR3 are important in the development of ANCA-associated pauci-immune GN. 247 PR3 and elastase also induce EC apoptosis. 233, 248 Activated ECs also contribute to a procoagulant environment. 211 Intraglomerular fibrin deposition and enhanced tissue factor (TF) expression are prominent in ANCA-associated GN. 211, 249 Thrombosis and platelets play key roles in the pathogenesis of early lesions in ANCA-associated vasculitis. 250 The later phases of the vasculitic process in WG are mediated primarily by mononuclear cells. T-lymphocytes (primarily CD4 þ cells) in WG are activated and produce diverse cytokines/chemokines that favor a proinflammatory milieu. 208, 251, 252 Biopsies from lung, kidney, or upper respiratory tract in WG patients contain CD3 þ cells (predominantly CD4 þ ), many of which express human leukocyte antigen (HLA-DR) (indicating activation).
253 CD8 þ cells likely play contributory roles. 254 Circulating PR3 and MPO antigenspecific T cells are present in peripheral blood (PB) in patients with ANCA-associated vasculitis. 255, 256 Antigen-specific T cells persist in the PB in patients in remission, 255 suggesting that T cells contribute to late relapses.
Th1-like cytokines appear to be pivotal to the pathogenesis of WG. Peripheral blood mononuclear cells (PBMCs) 208 or T cells (CD4 þ cells) isolated from blood, BAL, or granulomatous lesions from patients with WG display increased secretion of IFNg but not IL-4, IL-5, or IL-10, consistent with a Th1 response. 257 Furthermore, TNFa production from PBMCs and CD4 þ T cells isolated from patients with WG is elevated when compared with healthy donors. 208 In vitro production of IFNg by WG PBMC is inhibited in a dose-dependent manner by exogenous IL-10. 208 Large numbers of CD3 þ T cells, IFNg-staining cells, and CD4 þ /CD26 þ cells (CD26 is a Th1 marker) were identified in granulomatous lesions of nasal biopsies from patients with WG. 258 In contrast, CD30 þ cells (a Th2 marker) were uncommon. 258 The immune response may be compartmentalized and may differ in localized versus disseminated disease. For example, Th1 cells predominated in nasal biopsies from patients with localized WG compared with generalized WG. 258 By contrast, PB mononuclear cells from localized WG displayed a Th2 phenotype when compared with generalized disease. 258 These data suggest a polarized Th1-like response in localized disease. The Th1 cytokine profile observed in WG is consistent with an immune response to antigens. T cells reacting to bacterial antigens produce a Th1 cytokine profile. 259 A shift in the bias from Th1 to Th2 profiles may occur at different phases of the disease. 258 Such a shift in T cell phenotype has been described in systemic vasculitis 260 and lepromatous leprosy. 261 The T cell bias in WG is neither straightforward nor static. In one study, Th2 bias (increased IL-4, decreased IFNg, increased expression of CCR3) predominated in nasal mucosal biopsies from patients with WG. 262 Interestingly, renal biopsies demonstrated both Th1 and Th2 responses (increased IL-2 and Il-4). 262 Expression of the chemokines monocyte chemoattractant peptide-1 (MCP-1), macrophage inflammatory protein (MIP-1a) , MIP-1b, and RANTES (regulated upon activation in normal T cells) is enhanced in ANCA-associated vasculitis. 263 These chemokines favor T cell recruitment. 264 Monocytes from patients with active WG secrete greater amounts of IL -12, 208 which favors the Th1 phenotype. Upregulation of B7-1 and B7-2 on activated T cells, with a lower expression of B7-2 on monocytes, promotes a Th1 cytokine response. 211 In addition, monocytes in WG release IL-8 264a and IL-12. 208 Macrophages (MO) are the predominant cells responsible for RANTES production in WG. 263 Memory T cells also play a role. In granulomatous lesions from patients with WG, the predominant populations comprised memory T cells (CD45RO þ ) (CD4 þ > CD8 þ ) and CD68 þ MOs; few B lymphocytes (either CD19 or CD20) were present. 263 Further, the chemokine RANTES (produced mainly by MOs) and the gene encoding for IFNg were expressed at a higher level in lung tissue from WG patients than in controls. 263 One can theorize that cANCA triggers an initial pathological event, which induces production of inflammatory cytokines, chemokines, and adhesion molecules. Later, T cells produce IFNg that stimulates RANTES production by MOs, which then recruits additional memory T cells and MOs. 263 Interestingly, corticosteroids inhibit T cell production of IFNg and RANTES production by MOs. 263 T lymphocytes lacking CD28 expression may play a pathogenic role in some autoimmune disorders including ulcerative colitis, 265 rheumatoid arthritis, 266, 267 and WG. 252, 254 Expansion of the CD28(-) subset of CD4 þ or CD8 þ cells in PB has been noted in WG 252, 254 and corresponds with greater extent of disease. 254 In addition, the proportion of CD28 negative T cells (both CD4 þ and CD8 þ ) in granulomatous lesions and BAL is increased in WG compared with active sarcoidosis or healthy controls. 268 Although T cells play a pivotal role in the inflammatory process in WG, B lymphocytes contribute. CD20 þ B lymphocytes and CD38 þ plasma cells were present in nasal biopsies from patients with untreated WG. 269 Activated CD4 þ cells of the Th2 type are present in PB in patients with generalized WG.
270
CD4
þ Th2 cells show B cell helper activity and stimulate antibody production. 271 B-lymphocyte production of cANCA is polyclonal. 272, 273 During active disease, IgG 1 and IgG 4 predominate, 273 with a slight increase in IgG 3 as well. 272 The presence of antibodies of the IgG 4 subclass suggests that ANCA production is antigen-triggered and T cell dependent. 274 One may speculate that B cells promote ANCA production elicited by S. aureus-reactive T cell clones. 275 Chronic infection may play a role in orchestrating the inflammatory/immune process in WG. Intercurrent bacterial or viral infections increase the risk for relapses in WG. 195 Chronic nasal carriage of S. aureus is a risk factor for disease relapses. 213 Mayet et al examined PB lymphocyte responses to PR-3, S. aureus, and other bacterial antigens. 275 Reactivity to S. aureus was increased in patients with WG compared with controls. Further, S. aureus-specific T cell clones from patients with WG were of the ab TCR þ CD4 þ phenotype and HLA-DR restricted. 275 In addition, S. aureus-specific T cell clones recognized the PR3 antigen. The authors speculated that specific HLA-DR restricted CD4
þ T cells play a key role in triggering immune responses in WG.
Genetic Factors
The role of genes in influencing susceptibility to WG has not been extensively studied. A Caucasian racial bias has been suggested, 2 281, 282 Genetic polymorphisms may influence susceptibility to autoimmune disorders (including WG). Certain polymorphisms of receptors for the Fc fragment of IgG (FcgR) (i.e., homozygosity for the R131 form of (FcgRIIa) for the R158 form of (FcgRIIIa) were associated with a higher propensity to relapse in the first 5 years after diagnosis of WG. 283 These polymorphisms are associated with decreased FcR-mediated clearance, 284 which may be relevant to the chronic nasal carriage of S. aureus. A link between a-1-antitrypsin proteinase inhibitor (Pi) Z allele and WG has been cited. [285] [286] [287] An increased frequency of the a-1-antitrypsin allele PiZ and members of the serpin gene cluster was noted in patients with WG. 288 a-antitypsin (a-AT) is the main inhibitor of PR3 and elastase.
211 PR3-ANCA interferes with the binding of PR3 to a-AT, and may inhibit the clearance of PR3. 211 In one study, the inhibitory effect of ANCA on PR3/a-AT correlated more closely with disease activity than serum levels of ANCA. 286 
Treatment
Over the past 30 years, WG has gone from being a fatal disease for which there was no known treatment to one TREATMENT OF WG/LYNCH ET AL in which there are therapeutic options capable of bringing about long-term survival. 2, 4 With the expansion of therapeutic alternatives, management decisions in WG are increasingly being guided by disease severity, organ manifestations, and individual patient factors that take into account past treatment history and drug toxicities. 289 Prior to the introduction of effective therapy, mean survival among patients with untreated active WG was less than 6 months 290 ; more than 80% of patients died within 3 years of onset of symptoms, usually of progressive renal failure. 291 Corticosteroids were initially employed and ameliorated many of the inflammatory manifestations of WG. However, gains in survival were modest (mean survival of only 12.5 months). 292 Early experience at the NIH affirmed that CS alone were not adequate to treat severe WG. In an early cohort of patients at that institution, 57 had initially been treated with CS. 2 Although partial improvement was sometimes cited, none of 45 patients with renal involvement achieved complete remissions with CS alone. Further, excessive cumulative doses of CS may lead to long-term adverse effects (particularly osteoporosis and opportunistic infections). 8 The seminal studies employing daily CYC combined with CS represented a major advance in the treatment of WG. 30 This regimen dramatically improved survival but underscored the need to broaden the therapeutic goals to include relapse prevention and minimization of treatment-related toxicity. In the original regimen by Fauci and Wolff, patients were treated with oral CYC (1-2 mg/kg/d) combined with prednisone (1 mg/kg/d, with gradual taper). 1, 30 Among responders, prednisone was gradually tapered to an alternate schedule and discontinued by 6 to 9 months. CYC was continued for a minimum of 1 year past remission and was then tapered and discontinued. From the NIH cohort spanning 1229 patient-years, 91% of patients treated with this regimen improved, 75% achieved complete remission (CR), and mortality was only 20%. 2 Unfortunately, relapses occurred in 50% of patients, and 42% experienced serious morbidity from the side effects of treatment. Subsequent studies employing this regimen reported remissions rates of 70 to 90% and early mortality rates less than 15%. 4, 119, 199, 291 Relapses were noted in 30 to 70% of patients following cessation or tapering of therapy, but reinstitution of therapy was usually efficacious. 4, 6, 293 However, late sequelae of vasculitis (e.g., cerebrovascular accidents, myocardial infarction, renal failure, hypertension) or complications of CYC (e.g., opportunistic infections, neoplasms) contributed to long-term mortality and morbidity. 2, 4, 8, [293] [294] [295] [296] The search has remained ongoing for safer and effective therapies associated with acceptable rates of relapse.
INTERMITTENT ''PULSE'' CYC
The exploration of intermittent high-dose intravenous (IV) ''pulse'' CYC in WG was prompted by the potential for reduced toxicity as well as favorable experience with this approach in other autoimmune diseases. Although data are limited, pulse CYC appears to be less effective than daily oral CYC for WG. 6, 293, 294, [297] [298] [299] [300] [301] [302] Several studies showed that remission rates were similar with oral or IV pulse CYC, but relapses were more common with pulse CYC. 293, 297, 299 It is possible that reducing the time between cycles or extending the total length of IV pulse therapy may improve long-term prognosis, but this has not been studied. Currently, we believe daily oral CYC combined with CS is optimal therapy for generalized WG. Recent treatment strategies advocate initial treatment with oral CYC and CS for 3 to 6 months (until CR are achieved), followed by maintenance therapy with less toxic agents (e.g., methotrexate or azathioprine) 4, [303] [304] [305] (discussed later).
METHOTREXATE
Oral or IV methotrexate (MTX), administered once weekly, may be used for patients developing serious adverse effects from CYC or for non-life-threatening WG. 303, 304, 306, 307 In an open-label prospective trial, investigators at the NIH treated 42 patients with oral MTX (20-25 mg once weekly) combined with prednisone (initial dose 1 mg/kg/d, with gradual taper). 306 All patients had active disease at entry, including GN in 21 (50%) and lung involvement in 22 (52%). Exclusion criteria included acute renal failure, pulmonary hemorrhage, serum creatinine > 2.5 mg%, and chronic liver disease. With this regimen, remissions were achieved in 30 patients (71%); overall survival was 93%. Late relapses occurred in 11 of 30 (36%), but reintroduction of MTX plus CS led to second remissions in six of eight patients. 306 Toxicity was generally mild, but four patients developed Pneumocystis carinii pneumonia (PCP) (two of whom died). Long-term follow-up (median of 76 months) of 21 patients with active GN in that study cited durable remissions in 20 patients (95%). 304 At late follow-up, the serum creatinine rose > 0.2 mg% from baseline in only two patients. In another open-label trial, these investigators treated 31 patients with WG with CYC plus prednisone. 308 After CRs were achieved (at a median of 3 months), CYC was discontinued and MTX was substituted to maintain remissions. Exclusion criteria for MTX included serum creatinine > 2.5 mg% or chronic liver disease. Late relapses occurred in five of 31 patients (16%); all relapses occurred more than 1 year after initiation of MTX. All five patients were taking only MTX at relapse; all five responded to intensification of therapy. In a similar study, de Groot and colleagues treated patients initially with either oral or IV pulse CYC and switched to weekly IV MTX with or without concomitant CS after remissions had been achieved with CYC. 309 Median duration of CYC in that study exceeded 24 months. Partial or complete remissions were maintained in 86% of 22 patients who received MTX alone and in 10 of 11 (91%) of patients receiving MTX plus prednisone. A subsequent report from these investigators documented favorable responses to IV pulse MTX in 10 of 17 patients (59%); in that study, lowdose CS was administered concomitantly (mean prednisone dose < 7 mg/d). 303 All 17 patients had active disease at entry; 11 had never been treated; six had relapsed after initial remission with CYC and CS. By 2000, these same investigators had treated 45 patients with IV pulse MTX for either initial or maintenance therapy for non-life-threatening WG. 4 Patients with impaired renal function were excluded. Among the entire cohort of 155 patients (92% received CYC at some point), overall mortality was only 14% after a median of 5.6 years. These various publications 4, 303, 304, 306, 307, 309, 310 are encouraging and support the use of MTX plus prednisone in patients experiencing adverse effects from CYC or as initial therapy for mild WG. Additional data are required to evaluate the role of MTX as therapy for severe cases of WG. Because the kidneys are the major route of MTX elimination, toxicity is increased in the presence of renal insufficiency. 311 Additionally, the concomitant use of MTX and therapeutic doses of 160 mg trimethoprim/800 mg sulfamethoxazole (T/S) twice daily may cause severe pancytopenia. 307, 311 Thrice weekly T/S (80/400) plus MTX can be safely administered 308 and is recommended as prophylaxis against PCP. 306, 307, 310, 312 AZATHIOPRINE Azathioprine (AZA) is less effective than CYC and should not be used as primary therapy for WG. However, AZA (1-3 mg/kg/d orally) has a role as maintenance therapy in patients who remit with CYC and CS. Early studies cited maintenance of remission with AZA in eight of nine 1 and 10 of 13 313 patients after initial induction of remission with CYC and CS. Although AZA has myriad potential toxicities, including bone marrow suppression, heightened susceptibility to infections, GI toxicities, stomatitis, and idiosyncratic reactions, serious adverse effects requiring discontinuation of therapy are uncommon (< 10%). 295 In contrast to CYC, AZA lacks bladder toxicity and has low oncogenic potential. 295 
STAGED ''INDUCTION-MAINTENANCE'' THERAPY OF WG
Although CYC remains the cornerstone of therapy for generalized or severe WG, long-term cumulative use or the need for repetitive courses of CYC to treat relapses may be associated with serious potential toxicities (particularly bladder carcinomas and myeloproliferative disorders). 2, 295, 296, [314] [315] [316] [317] Recent strategies advocate treating generalized WG with CYC and CS (to induce remission), followed by less toxic agents (e.g., AZA or MTX) to maintain remissions. 305, 308, 309 A recent randomized trial by the European Vasculitis Study Group presented strong evidence in support of this ''induction-maintenance'' approach in WG. 305 In that study, 155 patients with ANCA-associated vasculitis were treated with daily oral CYC/CS as induction therapy for a minimum of 3 to 6 months. 305 Ninety-five patients (61%) had WG; 60 patients (39%) had MPA. Renal involvement was present in 94%. With this induction regimen, CRs were achieved in 119 patients (77%) by 3 months and in 144 patients (93%) within 6 months. After CRs were achieved, patients were randomly assigned to continue oral CYC (1.5 mg/kg/ d) (n ¼ 73) or switch to AZA (2 mg/kg/d) (n ¼ 71) in addition to low-dose prednisolone (10 mg/d) for maintenance therapy. After 12 months of therapy, both groups received AZA (1.5 mg/kg/d) and prednisolone (7.5 mg/d). Both groups were followed for 18 months from study entry. At 18 months, relapse rates (the primary end point) were similar in the AZA cohort (15.5%) and CYC group (14%) (p ¼ 0.65). Relapses were more common among patients with WG (18%) compared with MPA (8%), p ¼ 0.03. Other outcome measures (e.g., Vasculitis Damage Index scores, quality of life, CRP, or ESR) were similar between AZA and CYC cohorts. End-stage renal failure developed in two patients in each group. The rate of adverse effects was similar between treatment groups. Only eight patients died (5% mortality). Seven of the eight fatalities occurred within the first 3 months, during the induction phase with CYC/CS. One patient died (from stroke) during the maintenance phase. Although the frequency of toxicity was similar between treatment arms, the short study duration was insufficient to examine the long-term consequences associated with chronic CYC use (particularly malignancies). This experience supports the use of CYC/CS for initial induction therapy, followed by early switch (within 3 to 6 months) to less toxic agents once CRs have been achieved. Although this study did not evaluate MTX, either MTX or AZA are reasonable options for long-term maintenance therapy. The decision about whether to use MTX or AZA for remission maintenance must be made on an individual patient basis because no studies have directly compared these agents. However, MTX is contraindicated in patients with renal insufficiency, hepatic disease, or severe chronic pulmonary functional impairment.
MYCOPHENOLATE MOFETIL
Mycophenolate mofetil (MMF), an inhibitor of purine synthesis, has been used in small, nonrandomized trials as a remission maintenance agent in WG. In one study, nine patients with WG were treated with MMF (2 g/d) following induction of remission with CYC/CS. 318 One patient relapsed during the 15-month study period. In a prospective study, Langford et al treated 14 patients with daily CYC plus CS to induce CR, followed by MMF as maintenance therapy. 319 Relapses occurred in six patients (43%) at a median of 10 months after achieving CR. 319 Experience with MMF is limited; its use should be reserved for patients experiencing or at risk for adverse effects from MTX or AZA.
CHLORAMBUCIL
Chlorambucil, an alkylating agent related to CYC, 295 has been used to treat WG, with anecdotal successes, 26, 313 but is oncogenic and has myriad toxicities. 295 We see no role for chlorambucil to treat WG.
TRIMETHOPRIM/SULFAMETHOXAZOLE
Trimethoprim/sulfamethoxazole (T/S), one double strength tablet b.i.d., may reduce relapse rates in patients with WG 320 but is of doubtful value as primary therapy. 321 In seminal, nonrandomized studies, DeRemee and colleagues reported favorable responses to T/S alone or in combination with CYC/CS in patients with indolent or progressive WG. 322, 323 Given the nonrandomized nature of these studies and lack of rigorous end points, the impact of T/S was difficult to assess. A subsequent nonrandomized study cited favorable responses with T/S alone for limited, ''initial phase'' WG. 324 Another prospective study treated 72 WG patients with T/S, both to induce or sustain remissions. 28 Among 19 patients with initial-phase WG confined to the respiratory tract, partial or complete remissions (CR) were achieved in 11 (58%) with T/S alone. By contrast, among 53 patients with generalized WG, the addition of T/S 1 year after CR were achieved with CYC plus CS did not reduce late relapse rates. 28 A prospective study at the NIH noted no CR in any of nine WG patients treated with T/S (alone or combined with CS) as initial therapy. 321 Others reported that T/S was less effective than MTX in maintaining remissions following initial treatment with CYC and CS. 309 Nonetheless, a role for T/S in ameliorating the course of the disease is plausible. One placebo-controlled, randomized trial suggested that T/S reduced relapse rates in patients with WG who were in remission following treatment with CYC and CS. 320 T/S (160 mg/800 mg) or placebo twice daily was initiated only after CR were achieved with CYC and CS. Treatment with CYC and CS was continued and tapered as per conventional guidelines. After 24 months of follow-up, relapses had occurred in 18% of patients in the T/S cohort compared with 40% in the placebo group. Relapse rates were lower only with regard to upper respiratory tract disease, but not renal or lung involvement. Further, titers of ANCA did not differ between groups. These data are intriguing, but the impact of T/S on modulating the course of WG remains controversial. The mechanism of action of T/S is not known but could reflect antimicrobial or immunomodulatory effects. Relapses of WG are more frequent coincident with respiratory infections or in patients with chronic nasal carriage of S. aureus. 213 Low-grade bacterial infection may prime neutrophils to express target antigens (e.g., cANCA) on the cell surface and may trigger local immune responses. 213 The antimicrobial effect of T/S may abrogate these effects, thus limiting neutrophil activation and further tissue damage.
In view of its low toxicity, T/S may be considered as adjunctive therapy for persistent, indolent disease despite CYC and CS. Although T/S may be considered as initial therapy for selected patients with isolated upper airways disease, T/S has no primary role for treating WG involving kidneys or other major organs. The most important role of T/S in WG is to prevent pneumonia due to Pneumocystis jiroveci (formerly P. carinii), a well-known complication of immunosuppressive therapy. 293, 312, [325] [326] [327] The incidence of PCP in WG ranges from 20% in a French study 293 to 4% in the United States 2 and 1% in Germany 328 ; these differences likely reflect more aggressive immunosuppression in the French group. 293 Prophylaxis against PCP with T/S is highly efficacious 329, 330 and should be given to all patients treated with aggressive immunosuppressive therapy. Thrice weekly T/S (160 mg/800 mg) is costeffective. 329 Other prophylactic regimens employing dapsone, 331 aerosolized pentamadine (one monthly), 329, 332 or atovaquone 331 are far more expensive 329 and have a less favorable adverse effect profile.
TREATMENT OF FULMINANT DISEASE
More aggressive therapeutic regimens may be necessary in patients with fulminant disease [e.g., rapidly progressive glomerulonephritis (RPGN), DAH with respiratory failure, or CNS vasculitis]. In this context, higher initial doses of CS and CYC can be considered. 1 Pulse methylprednisolone (1000 mg daily IV) combined with IV CYC (3-4 mg/kg/d) for 3 days, followed by CS taper and oral CYC (2 mg/kg/d) has been used, but data are limited to anecdotal cases. This regimen is associated with an increased risk of side effects and should be considered only for life-threatening indications. Plasmapheresis (combined with CYC/CS) has been employed, with anecdotal successes in severe DAH, 333 but its efficacy remains unclear. 334 In the absence of prospective data establishing its efficacy apart from other modalities, plasmapheresis should be reserved for patients with lifethreatening disease refractory to conventional therapies.
Special Considerations WG in the elderly (age ! 65 years) is associated with an increased mortality rate 294, 335 and incidence of complications of therapy. 335 Because of the heightened susceptibility to opportunistic infections in elderly patients, 335, 336 less aggressive immunosuppressive therapy is warranted in this age group. Further, initial induction therapy with agents less toxic than CYC (such as MTX) can be considered in patients with localized or less severe disease and a more favorable prognosis. In one study, elevated serum creatinine ! 1.8 mg% or age ! 57 years were predictors of worse survival. 294 In this context, traditional induction therapy with CYC/CS is appropriate. The dose and duration of immunosuppressive and CS therapy need to be individualized. In one retrospective study from Norway, all 57 patients treated with CS and CYC achieved CRs. However, relapses occurred in 31 patients (60%) after a median of 18 months. 337 Relapses were associated with lower cumulative doses of CYC and prednisolone. 337 Careful longitudinal followup incorporating clinical, serological parameters (e.g., CRP, ESR, ANCA), and radiographic parameters are essential to guide efficacy of therapy and appropriate dosing and duration of medical therapy. 350 Campath-1H (a monoclonal antibody directed against CD52), 139,351 humanized anti-CD4 antibodies, 32 anti-thymyocyte globulin, 352 and etoposide 353, 354 but data are limited to a few cases in uncontrolled trials.
Other Therapeutic Options
Biological Response Modifiers
The use of biologic agents in the treatment of WG is currently being investigated. These therapies are intriguing because of the potential to specifically target immunologic components involved in disease pathogenesis while leaving other host defense mechanisms intact. The study of biologic therapies in WG must, however, be approached with caution because of the potential for unexpected effects in a disease that can be life threatening. To date, the efficacy and safety profile associated with biologic agents to treat WG have not been established. A chapter later in this issue by Lanford addresses the rationale and published data for the use of biologic therapies in WG.
